VERSATILE CLINICAL USE OF ROSUVASTATIN: SHOULD ITS LIPID-LOWERING PROPERTIES BE RELIED ON?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper shows both the lipid-lowering and pleiotropic (non-lipid) effects of rosuvastatin and experimental and clinical backgrounds for its use as both mono- and combination therapy in patients with cardiovascular and associated diseases.

Full Text

Restricted Access

References

  1. Гиляревский С.Р., Орлов В.А., Кузьмина И.М. и др. Гиполипидемические эффекты применения интенсивных режимов приема статинов при лечении больных с острым коронарным синдромом: подходы к выбору препарата и его дозы // Кардиология и сердечно-сосудистая хирургия. - 2012; 4: 36-41.
  2. Зубарева М., Рожкова Т., Горнякова Н. и др. Эффективность, безопасность и переносимость терапии розувастатином у больных очень высокого cердечно-cосудистого риска с первичной гиперхолестеринемией. Предварительные результаты исследования «40x40» // Врач. - 2012; 2: 61-5.
  3. Amarenco P., Labreuche J., Lavallee P. et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis // Stroke. -2004; 35: 2902-9.
  4. Barnes P., Celli B. Systemic manifestations and comorbities in COPD // Eur. Respir. J. - 2009; 33: 1165-85.
  5. Birmingham B., Swan S., Puchalski T. et al. Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis // Clin. Drug. Investig. - 2013 (Epub. ahead of print).
  6. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration // Lancet. -1995; 346: 1647-53.
  7. Crouse J. 3rd, Raichlen J., Riley W. et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial // JAMA. - 2007; 297 (12): 1344-53.
  8. Garcia-Rodriguez L., Massó-González E., Wallander M. et al. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care // Pharmacoepidemiol. Drug. Saf. - 2008;17 (10): 943-52. doi: 10.1002/pds.1603.
  9. Germershausen J., Hunt V., Bostedor R. et al. Tissue selectivity of the cholesterol-lowering agentslovastatin, simvastatin and pravastatin in rats in vivo // Biochem. Biophys. Res. Commun. - 1989; 158: 667-75.
  10. Goldstein J., Brown M. Regulation of the mevalonate pathway // Nature. -1990; 343: 425-30.
  11. Horwich T., MacLellan W., Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure // J.Am. CollCardiol. -2004; 43: 642-8.
  12. Kilic U., Bassetti C., Kilic E. et al. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellularregulated kinase-1/-2 // Neuroscience. - 2005; 134: 901-6.
  13. Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure // N. Engl. JMed. - 2007; 357: 2248-61.
  14. Kostapanos M., Milionis H., Elisaf M. An overview of the extra-lipid effects of rosuvastatin // J. Cardiovasc. Pharmacol. Ther. - 2008; 13 (3): 157-74. doi: 10.1177/1074248408318628. Epub 2008 May 6.
  15. LaRosa J., Grundy S., Waters D. et al. For the Treating to New Targets (TNT) Investigators.Intensive lipid lowering with atorvastatin in patients with stablecoronary disease // N. Engl. J. Med. - 2005; 352: 1-11.
  16. McKenney J., Jones P., Adamczyk M. et al. STELLAR Study Group. Comparison of the efficacy of rosuvastatinversusatorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial // Curr. Med. Res. Opin. - 2003; 19 (8): 689-98.
  17. McTaggart F. Comparative pharmacology of rosuvastatin // Atheroscler. -2003; 4: 9-14.
  18. Nassief A., Marsh J. Statin therapy for stroke prevention // Stroke. - 2008; 39: 1042-8.
  19. Nissen S., Nicholls S., Sipahi I. et al. Effect of very highintensitystatin therapy on regression of coronary atherosclerosis: the ASTEROID trial // JAMA. -2006; 295 (13): 1556-65.
  20. Node K., Fujita M., Kitakaze M. et al. Short-term statin therapy improves cardiac functionand symptoms in patients with idiopathic dilated cardiomyopathy // Circulation. - 2003; 108: 839-43.
  21. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering // Arterioscler. Thromb. Vasc. Biol. - 2001; 21: 3-5.
  22. Pitt B., Loscalzo J., Monyak J. et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study) // Am. J. Cardiol. - 2012; 109 (9): 1239-46. doi: 10.1016/j. amjcard.2011.12.015. Epub. 2012 Feb 21.
  23. Prinz V., Laufs U., Gertz K. et al. Intravenous rosuvastatin for acute stroke treatment: an animal study // Stroke. - 2008; 39: 433-8.
  24. Rasmussen F., Mikkelsen D., Hancox R. et al. High-sensitive Creactive protein is associated with reduced lung function in adults // Eur. Respir. J. - 2009; 33: 382-8.
  25. Ridker P. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial // Circulation. - 2003; 108: 2292-7.
  26. Ridker P., Cannon C., Morrow D. et al. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. - 2005; 352: 20-8.
  27. Sever P., Poulter N., Wedel H. et al. For the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial // Lancet. - 2003; 361: 1149-58.
  28. Schmidt W., Spiel A., Jilma B. et al. In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model // Pharmacogenet. Genomics. - 2008; 18: 109-20.
  29. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk // Expert. Rev. Cardiovasc. Ther. - 2007; 5: 177-93.
  30. Sironi L., Gianazza E., Gelosa P. et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects // Arterioscler. Thromb. Vasc. Biol. - 2005; 25: 598-603.
  31. Strippoli G., Navaneethan S. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials // BMJ. - 2008; 336: 645-51.
  32. Van Aelst L., D'Souza Schorey C. RhoGTPases and signaling networks // Genes. Dev. - 1997; 11: 2295-322.
  33. Vidt D., Cressman M., Harris S., Pears J. et al. Rosuvastatin-induced arrest in progression of renal disease // Cardiology. - 2004; 102 (1): 52-60. Epub. 2004 Apr. 2.
  34. Wang C., Liu P., Liao J. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results // Trends. Mol. Med. - 2008; 14: 37-44.
  35. Ikeda H., Takajo Y., Murohara T. et al. Platelet-derived nitric oxide and coronary risk factors // Hypertension. - 2000; 35: 904-7.
  36. Kaneider N., Egger P., Dunzendorfer S., Wiedermann C. Rho-GTPase-dependentplateletneutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function // Arterioscler. Thromb. Vasc. Biol. - 2002; 22: 1029-35.
  37. Greenwood J., Steinman L., Zamvil S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation // Nat. Rev. Immunol. -2006; 6: 358-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies